The updated data are consistent with results from the primary analysis for PALOMA-2, which showed a median PFS for women treated with IBRANCE plus letrozole of 24.8 months (95% CI: 22.1, NE ...

In AMEERA-5 (ClinicalTrials.gov identifier: NCT04478266), a double-blind, double-dummy, international phase III trial, adult pre-/post-menopausal women and men without previous systemic therapy for ...

Lab abnormalities of any grade occurring in PALOMA-2 for IBRANCE plus letrozole vs placebo plus letrozole were decreased WBC (97% vs 25%), decreased neutrophils (95% vs 20%), anemia (78% vs 42% ...

A sub-group analysis of the MONALEESA-2 trial indicates that the combination of ribociclib and letrozole may increase survival in advanced breast cancer.

Women were eligible for letrozole treatment (2.5 mg/d for six months) if they were postmenopausal, HR+, had early stage breast cancer, and experienced grade 2-3 A/M on anastrozole resulting in ...

Feb. 13, 2004 — The combination of the aromatase inhibitor letrozole and the progestin norethindrone acetate is effective and well tolerated for women poorly responsive to medical and surgical ...

Levels of estrogen in patients receiving treatment were greater at higher levels of BMI with both aromatase inhibitors, but whereas this was significant with letrozole (r=0.35; P=.013 for ...

EAST HANOVER, N.J., June 2, 2017 /PRNewswire/ -- Novartis announced today updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali ® (ribociclib ...

We report an open-label, prospective, crossover study involving 184 post-menopausal women experiencing hot flushes on adjuvant tamoxifen (T). Six weeks after switching to an AI, the primary end ...